{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:41:44Z","timestamp":1791423704321,"version":"4.3.3"},"reference-count":161,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acromegaly is associated with increased mortality rates if not adequately treated. Cardiovascular and metabolic comorbidities are highly prevalent and have long been considered the main cause of death among patients with acromegaly. However, substantial advances in GH\/IGF-I-lowering treatment, together with increased awareness and optimized management of other risk factors, have led to major improvements in mortality rates in the 2-3 past decades. Here, we review the effects of chronic excessive GH\/IGF-I production and the successful treatment of this condition on relevant classical cardiovascular risk factors and on morphological and functional changes in the heart and discuss differences in reported prevalence rates over time according to different imaging methodologies used. Although morphological alterations (ie, myocardial hypertrophy as well as increased atrial and ventricular volumes) are common in patients with acromegaly, overt clinically relevant dysfunction is rare. Valvular cardiac disease and arrhythmia are also reviewed. Clinically relevant cardiomyopathy is currently less common than previously estimated. Recent epidemiological studies have shown that the risk of heart failure is comparable to that of the general population after adjusting for biochemical disease control and other risk factors.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf338","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T07:23:49Z","timestamp":1749453829000},"page":"2718-2728","source":"Crossref","is-referenced-by-count":9,"title":["Cardiomyopathy in Patients With Acromegaly \u2013 Not Truly a Concern Anymore?"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-734X","authenticated-orcid":false,"given":"Peter","family":"Wolf","sequence":"first","affiliation":[{"name":"Medical University of Vienna, Department of Internal Medicine III, Division of Endocrinology and Metabolism \u00a0 Vienna 1090 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-8046","authenticated-orcid":false,"given":"Luigi","family":"Maione","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse (HYPO), Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre 94275 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4226","authenticated-orcid":false,"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse (HYPO), Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre 94275 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse (HYPO), Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre 94275 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"4","key":"2025091917023501300_dgaf338-B1","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025091917023501300_dgaf338-B2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"12","key":"2025091917023501300_dgaf338-B3","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025091917023501300_dgaf338-B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"issue":"5","key":"2025091917023501300_dgaf338-B5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2025091917023501300_dgaf338-B6","doi-asserted-by":"crossref","first-page":"1380436","DOI":"10.3389\/fendo.2024.1380436","article-title":"Changes in acromegaly comorbidities, treatment, and outcome over three decades : a nationwide cohort study","volume":"15","author":"Rosendal","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025091917023501300_dgaf338-B7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade : a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6)","key":"2025091917023501300_dgaf338-B8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cen.15060","article-title":"Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels \u2014 a retrospective analysis from the UK acromegaly register 1970\u20132016","volume":"100","author":"Orme","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025091917023501300_dgaf338-B9","doi-asserted-by":"crossref","first-page":"102921","DOI":"10.1016\/j.arcmed.2023.102921","article-title":"Acromegalic cardiomyopathy: an entity on its own? The effects of GH and IGF-I excess and treatment on cardiovascular risk factors","volume":"54","author":"Wolf","year":"2023","journal-title":"Arch Med Res"},{"issue":"3-4","key":"2025091917023501300_dgaf338-B10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ando.2020.03.010","article-title":"Cardiovascular complications of acromegaly","volume":"82","author":"Kamenick\u00fd","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2025091917023501300_dgaf338-B11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2265.2008.03323.x","article-title":"Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly","volume":"70","author":"Boero","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2025091917023501300_dgaf338-B12","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1210\/jc.2016-1937","article-title":"The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes","volume":"101","author":"Portocarrero-Ortiz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B13","doi-asserted-by":"crossref","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2025091917023501300_dgaf338-B14","doi-asserted-by":"crossref","first-page":"577173","DOI":"10.3389\/fendo.2020.577173","article-title":"Hypertension in acromegaly in relationship to biochemical control and mortality : global ACROSTUDY outcomes","volume":"11","author":"Vila","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2025091917023501300_dgaf338-B15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/EJE-16-0562","article-title":"Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly","volume":"175","author":"Sardella","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025091917023501300_dgaf338-B16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ecl.2019.08.008","article-title":"Hypertension and acromegaly","volume":"48","author":"Puglisi","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"2025091917023501300_dgaf338-B17","first-page":"465","article-title":"Reversible plasma and red blood cells volumes increases in acromegaly","volume":"85","author":"Strauch","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"7","key":"2025091917023501300_dgaf338-B18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1172\/JCI102977","article-title":"Body water and sodium in patients with acromegaly","volume":"33","author":"Ikkos","year":"1954","journal-title":"J Clin Invest"},{"issue":"2","key":"2025091917023501300_dgaf338-B19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications","volume":"35","author":"Kamenick\u00fd","year":"2014","journal-title":"Endocr Rev"},{"issue":"7","key":"2025091917023501300_dgaf338-B20","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1210\/en.2008-0143","article-title":"Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly","volume":"149","author":"Kamenicky","year":"2008","journal-title":"Endocrinology"},{"issue":"7","key":"2025091917023501300_dgaf338-B21","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1210\/jc.2011-0078","article-title":"Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025091917023501300_dgaf338-B22","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3181\/0901-RM-34","article-title":"Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice","volume":"234","author":"Bielohuby","year":"2009","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"2025091917023501300_dgaf338-B23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2265.2000.00931.x","article-title":"Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor","volume":"52","author":"M\u00f8ller","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1-2","key":"2025091917023501300_dgaf338-B24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0303-7207(98)00148-8","article-title":"Effect of chronic GH overproduction on cardiac ANP expression and circulating ANP levels","volume":"144","author":"Dirsch","year":"1998","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2025091917023501300_dgaf338-B25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2265.1989.tb01267.x","article-title":"Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly","volume":"31","author":"McKnight","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2025091917023501300_dgaf338-B26","first-page":"2458","article-title":"Diurnal rhythm of plasma catecholamines in acromegaly","volume":"84","author":"Bondanelli","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025091917023501300_dgaf338-B27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41574-022-00702-6","article-title":"Covert actions of growth hormone : fibrosis, cardiovascular diseases and cancer","volume":"18","author":"Kopchick","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2025091917023501300_dgaf338-B28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fendo.2019.00509","article-title":"Insulin resistance in patients with acromegaly","volume":"10","author":"Vila","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025091917023501300_dgaf338-B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","article-title":"Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients","volume":"17","author":"Alexopoulou","year":"2014","journal-title":"Pituitary"},{"issue":"10","key":"2025091917023501300_dgaf338-B30","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/diabetes.50.10.2301","article-title":"Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure","volume":"50","author":"Nielsen","year":"2001","journal-title":"Diabetes"},{"issue":"5","key":"2025091917023501300_dgaf338-B31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Impaired \u03b2-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients","volume":"52","author":"Kasayama","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025091917023501300_dgaf338-B32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-10-1096","article-title":"Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved","volume":"164","author":"Kinoshita","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025091917023501300_dgaf338-B33","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1038\/s41598-019-41887-7","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) resistance and \u03b2-cell dysfunction contribute to hyperglycaemia in acromegaly","volume":"9","author":"Shekhawat","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"2025091917023501300_dgaf338-B34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev"},{"issue":"3","key":"2025091917023501300_dgaf338-B35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41574-019-0280-9","article-title":"The effects of growth hormone on adipose tissue: old observations, new mechanisms","volume":"16","author":"Kopchick","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2025091917023501300_dgaf338-B36","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2007-2780","article-title":"Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly","volume":"93","author":"Freda","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-21-0900","article-title":"Treatment of acromegaly has substantial effects on body composition. A long-term follow-up study","volume":"186","author":"Wolf","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025091917023501300_dgaf338-B38","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1093\/ejendo\/lvae016","article-title":"Long-term depot specific changes in adipose tissue after treatment of acromegaly","volume":"190","author":"Falch","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2025091917023501300_dgaf338-B39","doi-asserted-by":"crossref","first-page":"1075776","DOI":"10.3389\/fendo.2023.1075776","article-title":"Ectopic lipid metabolism in anterior pituitary dysfunction","volume":"14","author":"Baumgartner","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2025091917023501300_dgaf338-B40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"issue":"15-16","key":"2025091917023501300_dgaf338-B41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s10354-014-0292-y","article-title":"Intracellular lipid accumulation and shift during diabetes progression","volume":"164","author":"Wolf","year":"2014","journal-title":"Wiener Medizinische Wochenschrift"},{"issue":"11","key":"2025091917023501300_dgaf338-B42","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1210\/jc.2014-2242","article-title":"No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy","volume":"99","author":"Winhofer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025091917023501300_dgaf338-B43","doi-asserted-by":"crossref","first-page":"e134638","DOI":"10.1172\/jci.insight.134638","article-title":"Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly","volume":"5","author":"Fellinger","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"2025091917023501300_dgaf338-B44","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/jc.2015-1917","article-title":"Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment","volume":"100","author":"Reyes-Vidal","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025091917023501300_dgaf338-B45","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/jc.2017-01210","article-title":"Body composition and ectopic lipid changes with biochemical control of acromegaly","volume":"102","author":"Bredella","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025091917023501300_dgaf338-B46","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1210\/clinem\/dgad206","article-title":"Increased GH\/IGF-I axis activity relates to lower hepatic lipids and phosphor metabolism","volume":"108","author":"Fellinger","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025091917023501300_dgaf338-B47","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1210\/clinem\/dgac088","article-title":"Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease","volume":"107","author":"Dichtel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41574-024-01037-0","article-title":"Liver-specific actions of GH and IGF1 that protect against MASLD","volume":"21","author":"Kineman","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2025091917023501300_dgaf338-B49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tem.2016.02.005","article-title":"The impact of adipose tissue on insulin resistance in acromegaly","volume":"27","author":"Olarescu","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"3-4","key":"2025091917023501300_dgaf338-B50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000371818","article-title":"The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment","volume":"103","author":"Olarescu","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2025091917023501300_dgaf338-B51","doi-asserted-by":"crossref","first-page":"101667","DOI":"10.1016\/j.beem.2022.101667","article-title":"Best practice & research clinical endocrinology & metabolism effects of endocrine disorders on lipids and lipoproteins","volume":"37","author":"Newman","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2025091917023501300_dgaf338-B52","doi-asserted-by":"publisher","first-page":"EP744","DOI":"10.1530\/endoabs.90.EP744","article-title":"Growth hormone treatment tends to promote hepatic VLDL1-triglyceride export in humans. Presented at 25th European Congress of Endocrinology.","volume":"90","author":"Baumgartner","year":"2023","journal-title":"Endocr Abstr"},{"issue":"4","key":"2025091917023501300_dgaf338-B53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2265.2012.04414.x","article-title":"GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly","volume":"77","author":"Boero","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025091917023501300_dgaf338-B54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archinte.1985.00360050121021","article-title":"Sleep apnea in active acromegaly","volume":"145","author":"Hart","year":"1985","journal-title":"Arch Intern Med"},{"issue":"4","key":"2025091917023501300_dgaf338-B55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-07-0753","article-title":"Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging","volume":"158","author":"van Haute","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025091917023501300_dgaf338-B56","doi-asserted-by":"crossref","first-page":"e010440","DOI":"10.1161\/JAHA.118.010440","article-title":"Obstructive sleep apnea in cardiovascular disease: a review of the literature and proposed multidisciplinary clinical management strategy","volume":"8","author":"Tietjens","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2025091917023501300_dgaf338-B57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","article-title":"Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease","volume":"159","author":"Davi\u2019","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2025091917023501300_dgaf338-B58","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1210\/jc.2013-4288","article-title":"Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea","volume":"99","author":"Chemla","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2009-1912","article-title":"Endocrine aspects of obstructive sleep apnea","volume":"95","author":"Attal","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025091917023501300_dgaf338-B60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2213-2600(12)70051-6","article-title":"Obstructive sleep apnoea and cardiovascular disease","volume":"1","author":"S\u00e1nchez-de-la-Torre","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2025091917023501300_dgaf338-B61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/edrv-15-5-555","article-title":"Growth hormone and the heart","volume":"15","author":"Sacc\u00e0","year":"1994","journal-title":"Endocr Rev"},{"issue":"1","key":"2025091917023501300_dgaf338-B62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"issue":"3","key":"2025091917023501300_dgaf338-B63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.2008.03292.x","article-title":"The GH-IGF-I axis and the cardiovascular system: clinical implications","volume":"69","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025091917023501300_dgaf338-B64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/157340309788970306","article-title":"The GH \/ IGF-1 axis and heart failure","volume":"5","author":"Castellano","year":"2009","journal-title":"Curr Cardiol Rev"},{"issue":"3","key":"2025091917023501300_dgaf338-B65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/clc.22867","article-title":"Acromegalic cardiomyopathy : epidemiology, diagnosis, and mana36gement","volume":"41","author":"Sharma","year":"2018","journal-title":"Clin Cardiol"},{"issue":"2","key":"2025091917023501300_dgaf338-B66","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1172\/JCI114737","article-title":"Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle","volume":"86","author":"Timsit","year":"1990","journal-title":"J Clin Invest"},{"issue":"1","key":"2025091917023501300_dgaf338-B67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.RES.83.1.50","article-title":"Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to ca2 + through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles","volume":"83","author":"Cittadini","year":"1998","journal-title":"Circ Res"},{"issue":"4","key":"2025091917023501300_dgaf338-B68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.31083\/j.rcm2404095","article-title":"Cardiovascular effects of excess growth hormone: how real is the threat?","volume":"24","author":"Rivera","year":"2023","journal-title":"Rev Cardiovasc Med"},{"issue":"5","key":"2025091917023501300_dgaf338-B69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2002.01528.x","article-title":"Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy","volume":"56","author":"Herrmann","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025091917023501300_dgaf338-B70","first-page":"196","article-title":"Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography","volume":"36","author":"Cuocolo","year":"1995","journal-title":"J Nucl Med"},{"issue":"9","key":"2025091917023501300_dgaf338-B71","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1210\/jc.2003-030462","article-title":"Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly","volume":"88","author":"Spinelli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2025091917023501300_dgaf338-B72","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJM199910213411706","article-title":"Signaling pathways for cardiac hypertrophy and failure","volume":"341","author":"Hunter","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"2025091917023501300_dgaf338-B73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients","volume":"100","author":"Lie","year":"1980","journal-title":"Am Heart J"},{"issue":"5","key":"2025091917023501300_dgaf338-B74","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1073\/pnas.91.5.1686","article-title":"Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes","volume":"91","author":"Donath","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2025091917023501300_dgaf338-B75","doi-asserted-by":"crossref","first-page":"luae072","DOI":"10.1210\/jcemcr\/luae072","article-title":"Uncontrolled acromegaly resulting in the need for left ventricular assist device as bridge to heart transplant","volume":"2","author":"Murugesh","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"19","key":"2025091917023501300_dgaf338-B76","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2169\/internalmedicine.49.3972","article-title":"A case of juvenile acromegaly that was initially diagnosed as severe congestive heart failure from acromegaly-induced dilated cardiomyopathy","volume":"49","author":"Sue","year":"2010","journal-title":"Intern Med"},{"issue":"1","key":"2025091917023501300_dgaf338-B77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13256-019-2030-y","article-title":"Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a case report","volume":"13","author":"Wang","year":"2019","journal-title":"J Med Case Rep"},{"issue":"2","key":"2025091917023501300_dgaf338-B78","doi-asserted-by":"crossref","first-page":"e18841","DOI":"10.5812\/ijem.18841","article-title":"Acromegaly with cardiomyopathy, cardiac thrombus and hemorrhagic cerebral infarct: a case report of therapeutic dilemma with review of literature","volume":"13","author":"Mendoza","year":"2015","journal-title":"Int J Endocrinol Metab"},{"issue":"8649","key":"2025091917023501300_dgaf338-B79","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(89)92355-6","article-title":"Heart failure responding to octreotide in patient with acromegaly","volume":"1","author":"Chanson","year":"1989","journal-title":"Lancet (London, England)"},{"issue":"9","key":"2025091917023501300_dgaf338-B80","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2169\/internalmedicine.48.1537","article-title":"Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly","volume":"48","author":"Akaza","year":"2009","journal-title":"Intern Med"},{"issue":"12","key":"2025091917023501300_dgaf338-B81","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2015-2675","article-title":"Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort","volume":"100","author":"Dos Santos Silva","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ejendo\/lvad105","article-title":"Increase in intracellular and extracellular myocardial mass in patients with acromegaly: a cardiac magnetic resonance imaging study","volume":"189","author":"Wolf","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025091917023501300_dgaf338-B83","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11102-024-01403-1","article-title":"The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study","volume":"27","author":"Alcubierre","year":"2024","journal-title":"Pituitary"},{"key":"2025091917023501300_dgaf338-B84","doi-asserted-by":"crossref","first-page":"2018464","DOI":"10.1155\/2020\/2018464","article-title":"Cardiac abnormalities in acromegaly patients: a cardiac magnetic resonance study","volume":"2020","author":"Guo","year":"2020","journal-title":"Int J Endocrinol"},{"key":"2025091917023501300_dgaf338-B85","doi-asserted-by":"crossref","first-page":"598948","DOI":"10.3389\/fendo.2020.598948","article-title":"Reversibility of cardiac involvement in acromegaly patients after surgery: 12-month follow-up using cardiovascular magnetic resonance","volume":"11","author":"Guo","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2025091917023501300_dgaf338-B86","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11102-023-01321-8","article-title":"Importance of 24\u2005hours ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings","volume":"26","author":"Rocha","year":"2023","journal-title":"Pituitary"},{"issue":"4","key":"2025091917023501300_dgaf338-B87","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11102-010-0240-9","article-title":"Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides","volume":"13","author":"Andreassen","year":"2010","journal-title":"Pituitary"},{"issue":"5","key":"2025091917023501300_dgaf338-B88","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/EJE-11-0408","article-title":"Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study","volume":"165","author":"Colao","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025091917023501300_dgaf338-B89","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2265.2005.02265.x","article-title":"Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study","volume":"62","author":"Bogazzi","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2025091917023501300_dgaf338-B90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the li\u00e8ge acromegaly survey (LAS) database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025091917023501300_dgaf338-B91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025091917023501300_dgaf338-B92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1536\/ihj.53.299","article-title":"Evaluation of left ventricular diastolic function according to new criteria and determinants in acromegaly","volume":"53","author":"Akdeniz","year":"2012","journal-title":"Int Heart J"},{"issue":"1","key":"2025091917023501300_dgaf338-B93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2265.2012.04472.x","article-title":"Acromegalic cardiomyopathy in an extensively admixed population: is there a role for GH\/IGF-I axis?","volume":"78","author":"Nascimento","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025091917023501300_dgaf338-B94","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.endonu.2015.05.007","article-title":"Severe sleep apnea-hypopnea syndrome is related to left ventricle dysfunction and hypertrophy in acromegalic patients","volume":"62","author":"Sanchez-Ortiga","year":"2015","journal-title":"Endocrinol Nutr"},{"issue":"1","key":"2025091917023501300_dgaf338-B95","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1590\/S0004-27302006000100012","article-title":"[Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly]","volume":"50","author":"Casini","year":"2006","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"1","key":"2025091917023501300_dgaf338-B96","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11102-007-0062-6","article-title":"The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly","volume":"11","author":"De Marinis","year":"2008","journal-title":"Pituitary"},{"issue":"1","key":"2025091917023501300_dgaf338-B97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12902-017-0166-6","article-title":"The association between biochemical control and cardiovascular risk factors in acromegaly","volume":"17","author":"Carmichael","year":"2017","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2025091917023501300_dgaf338-B98","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1530\/EJE-15-0500","article-title":"Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study","volume":"173","author":"Kuhn","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025091917023501300_dgaf338-B99","first-page":"1086","article-title":"American society of echocardiography recommendations for use of echocardiography in clinical trials","volume":"17","author":"Gottdiener","year":"2004","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"2025091917023501300_dgaf338-B100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","article-title":"Low frequency of cardiac arrhythmias and lack of structural heart disease in medically naive acromegaly patients : a prospective study at baseline and after 1 year of somatostatin analogs treatment","volume":"19","author":"Warszawski","year":"2016","journal-title":"Pituitary"},{"issue":"10","key":"2025091917023501300_dgaf338-B101","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jcmg.2020.06.026","article-title":"Aldosterone-related myocardial extracellular matrix expansion in hypertension in humans","volume":"13","author":"Redheuil","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"38","key":"2025091917023501300_dgaf338-B102","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/eurheartj\/ehac393","article-title":"Phenotyping the hypertensive heart","volume":"43","author":"Tadic","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"2025091917023501300_dgaf338-B103","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0008-6363(98)00181-3","article-title":"Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction","volume":"40","author":"Grimm","year":"1998","journal-title":"Cardiovasc Res"},{"issue":"5","key":"2025091917023501300_dgaf338-B104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1507\/endocrj.44.655","article-title":"Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide","volume":"44","author":"Nishiki","year":"1997","journal-title":"Endocr J"},{"issue":"1","key":"2025091917023501300_dgaf338-B105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000438903","article-title":"Cardiovascular disease and sleep- disordered breathing in acromegaly","volume":"103","author":"Powlson","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2025091917023501300_dgaf338-B106","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-x","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients","volume":"100","author":"Lie","year":"1980","journal-title":"Am Heart J"},{"issue":"6","key":"2025091917023501300_dgaf338-B107","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2214\/AJR.07.2031","article-title":"Rapidly reversible myocardial edema in patients with acromegaly : assessment with ultrafast T2 mapping in a single- breath-hold","volume":"190","author":"Gouya","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"2025091917023501300_dgaf338-B108","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EC-17-0031","article-title":"Heart, lipids and hormones","volume":"6","author":"Wolf","year":"2017","journal-title":"Endocr Connect"},{"issue":"5","key":"2025091917023501300_dgaf338-B109","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40292-024-00667-9","article-title":"Myocardial mechanics in acromegaly: a meta - analysis of echocardiographic studies","volume":"31","author":"Gherbesi","year":"2024","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"3","key":"2025091917023501300_dgaf338-B110","first-page":"634","article-title":"Subclinical left atrial and ventricular dysfunction in acromegaly patients: a speckle tracking echocardiography study","volume":"118","author":"Koca","year":"2022","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"2025091917023501300_dgaf338-B111","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s42000-024-00558-7","article-title":"Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly","volume":"23","author":"Firlatan","year":"2024","journal-title":"Hormones (Athens)"},{"key":"2025091917023501300_dgaf338-B112","doi-asserted-by":"crossref","first-page":"812964","DOI":"10.3389\/fendo.2022.812964","article-title":"Subclinical ventricular dysfunction in long-term acromegaly assessed by speckle-tracking echocardiography","volume":"13","author":"Gadelha","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2025091917023501300_dgaf338-B113","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/echo.14285","article-title":"Normal values of left ventricular rotational parameters in healthy adults-insights from the three-dimensional speckle tracking echocardiographic MAGYAR-healthy study","volume":"36","author":"Korm\u00e1nyos","year":"2019","journal-title":"Echocardiography"},{"issue":"7","key":"2025091917023501300_dgaf338-B114","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/jc.2002-021099","article-title":"High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study","volume":"88","author":"Colao","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025091917023501300_dgaf338-B115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2265.2011.04067.x","article-title":"Aortic root ectasia in patients with acromegaly : experience at a single center","volume":"75","author":"Xavier","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025091917023501300_dgaf338-B116","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly","volume":"89","author":"Pereira","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025091917023501300_dgaf338-B117","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B118","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-08-0138","article-title":"Increased aortic root diameters in patients with acromegaly","volume":"159","author":"Klaauw","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025091917023501300_dgaf338-B119","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2265.2011.04131.x","article-title":"Aortic root ectasia in patients with acromegaly : an emerging complication","volume":"75","author":"Colao","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025091917023501300_dgaf338-B120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00380-007-1012-y","article-title":"Sudden death due to aortic rupture in acromegaly","volume":"23","author":"Maffei","year":"2008","journal-title":"Heart Vessels"},{"issue":"9","key":"2025091917023501300_dgaf338-B121","doi-asserted-by":"crossref","first-page":"E1714","DOI":"10.1210\/jc.2012-1833","article-title":"No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly","volume":"97","author":"Maione","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"2025091917023501300_dgaf338-B122","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehab822","article-title":"Acromegaly and cardiovascular outcomes : a cohort study","volume":"43","author":"Hong","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"2025091917023501300_dgaf338-B123","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.eurheartj.a060047","article-title":"Arrhythmia profile in acromegaly","volume":"13","author":"Kahaly","year":"1992","journal-title":"Eur Heart J"},{"issue":"2","key":"2025091917023501300_dgaf338-B124","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-012-9828-3","article-title":"QT dispersion in patients with acromegaly","volume":"43","author":"Unubol","year":"2013","journal-title":"Endocrine"},{"key":"2025091917023501300_dgaf338-B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545875","article-title":"Prevalence and characteristics of heart disease in patients with acromegaly in Colombia (RAPACO HEART study)","author":"Abreu-Lomba","year":"2025","journal-title":"Cardiology"},{"issue":"6","key":"2025091917023501300_dgaf338-B126","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","article-title":"Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-na\u00efve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment","volume":"19","author":"Warszawski","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"2025091917023501300_dgaf338-B127","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11102-014-0605-6","article-title":"Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues","volume":"18","author":"Comunello","year":"2015","journal-title":"Pituitary"},{"issue":"2","key":"2025091917023501300_dgaf338-B128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40618-020-01343-0","article-title":"Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?","volume":"44","author":"Parolin","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2025091917023501300_dgaf338-B129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic\u00eatre cohort, and review of the literature","volume":"63","author":"Briet","year":"2019","journal-title":"Endocrine"},{"issue":"4","key":"2025091917023501300_dgaf338-B130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/cen.12455","article-title":"The beneficial effect of acromegaly control on blood pressure values in normotensive patients","volume":"81","author":"Sardella","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2025091917023501300_dgaf338-B131","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/jc.2018-00325","article-title":"Persistence of diabetes and hypertension after multimodal treatment of acromegaly","volume":"103","author":"Gonzalez","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025091917023501300_dgaf338-B132","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12020-022-03261-y","article-title":"Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients?","volume":"80","author":"Chiloiro","year":"2023","journal-title":"Endocrine"},{"issue":"38","key":"2025091917023501300_dgaf338-B133","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"9","key":"2025091917023501300_dgaf338-B134","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","article-title":"Diabetes mellitus in patients with acromegaly : pathophysiology, clinical challenges and management","volume":"20","author":"Esposito","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2025091917023501300_dgaf338-B135","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"3","key":"2025091917023501300_dgaf338-B136","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12020-023-03352-4","article-title":"How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients","volume":"80","author":"Zaina","year":"2023","journal-title":"Endocrine"},{"issue":"2","key":"2025091917023501300_dgaf338-B137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc20-1983","article-title":"Gluconeogenesis, but not glycogenolysis, contributes to the increase in endogenous glucose production by SGLT-2 inhibition","volume":"44","author":"Wolf","year":"2021","journal-title":"Diabetes Care"},{"issue":"22","key":"2025091917023501300_dgaf338-B138","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMc1915808","article-title":"Eucaloric very-low-carbohydrate ketogenic diet in acromegaly treatment","volume":"382","author":"Coopmans","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2025091917023501300_dgaf338-B139","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-13-0060","article-title":"Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute","volume":"169","author":"Yoshida","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025091917023501300_dgaf338-B140","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1210\/jc.2017-00082","article-title":"Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly","volume":"102","author":"Quarella","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025091917023501300_dgaf338-B141","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","article-title":"Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review","volume":"73","author":"Zaina","year":"2021","journal-title":"Endocrine"},{"issue":"8","key":"2025091917023501300_dgaf338-B142","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat Med"},{"issue":"9493","key":"2025091917023501300_dgaf338-B143","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2025091917023501300_dgaf338-B144","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eem.11.82","article-title":"Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment","volume":"7","author":"Dav\u00ec","year":"2012","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"2025091917023501300_dgaf338-B145","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ejendo\/lvaf009","article-title":"The effect of first intervention on cardiac parameters in patients with acromegaly : a systematic review","volume":"192","author":"Huynh","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025091917023501300_dgaf338-B146","first-page":"1551","article-title":"Is the acromegalic cardiomyopathy reversible? Effect of 5\u2013year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025091917023501300_dgaf338-B147","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2265.2001.01343.x","article-title":"Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients","volume":"55","author":"Minniti","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025091917023501300_dgaf338-B148","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025091917023501300_dgaf338-B149","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","article-title":"Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly","volume":"55","author":"Auriemma","year":"2017","journal-title":"Endocrine"},{"issue":"12","key":"2025091917023501300_dgaf338-B150","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7326\/0003-4819-113-12-921","article-title":"Cardiovascular effects of the somatostatin analog octreotide in acromegaly","volume":"113","author":"Chanson","year":"1990","journal-title":"Ann Intern Med"},{"issue":"11","key":"2025091917023501300_dgaf338-B151","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1210\/jc.2004-0821","article-title":"Long-term outcome of patients with acromegaly and congestive heart failure","volume":"89","author":"Bihan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025091917023501300_dgaf338-B152","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40618-023-02257-3","article-title":"Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy","volume":"47","author":"Arosio","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2025091917023501300_dgaf338-B153","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-18-0015","article-title":"Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study","volume":"178","author":"Esposito","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2025091917023501300_dgaf338-B154","doi-asserted-by":"crossref","first-page":"1348972","DOI":"10.3389\/fendo.2024.1348972","article-title":"High mortality risk among women with acromegaly still persists","volume":"15","author":"Galoiu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025091917023501300_dgaf338-B155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11102-015-0700-3","article-title":"The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study","volume":"19","author":"Varadhan","year":"2016","journal-title":"Pituitary"},{"issue":"8","key":"2025091917023501300_dgaf338-B156","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025091917023501300_dgaf338-B157","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1210\/jc.2007-1213","article-title":"Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025091917023501300_dgaf338-B158","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1530\/EJE-09-0945","article-title":"Acromegaly per se does not increase the risk for coronary artery disease","volume":"162","author":"Akutsu","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025091917023501300_dgaf338-B159","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12020-015-0628-4","article-title":"Low risk of coronary artery disease in patients with acromegaly","volume":"50","author":"Dos Santos Silva","year":"2015","journal-title":"Endocrine"},{"issue":"6","key":"2025091917023501300_dgaf338-B160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11102-017-0827-5","article-title":"Incidence of myocardial infarction and stroke in acromegaly patients : results from the German acromegaly registry","volume":"20","author":"Sch\u00f6fl","year":"2017","journal-title":"Pituitary"},{"issue":"5","key":"2025091917023501300_dgaf338-B161","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11102-024-01405-z","article-title":"Cardiovascular risk in patients with acromegaly vs. Non-functioning pituitary adenoma following pituitary surgery : an active-comparator cohort study","volume":"27","author":"Stocker","year":"2024","journal-title":"Pituitary"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf338\/63455398\/dgaf338.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/10\/2718\/63455398\/dgaf338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/10\/2718\/63455398\/dgaf338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:02:55Z","timestamp":1758315775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/10\/2718\/8158601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":161,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf338","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,9]]}}}